Read this first
This is plain-language harm-reduction information, not medical advice. Peptides discussed here are research compounds; most are not approved for human use. People will use them either way — we would rather they have the facts.
BPC-157 and TB-500 are two different research peptides that are both talked about for tissue repair. BPC-157 is a short fragment linked to a protein in stomach juice, while TB-500 is a synthetic fragment related to thymosin beta-4. They work through different proposed routes, which is the main reason people combine them, but almost all the evidence for both comes from animal studies and anecdote, not human trials.
Both are research chemicals, not licensed medicines. Nothing here is medical advice, and nothing here is encouragement to buy or use anything. This is what is known, and what is not.
The short version
- BPC-157 is a 15-amino-acid peptide. See the full BPC-157 page. Most talked about for tendon, ligament, gut and soft-tissue healing.
- TB-500 is a synthetic fragment related to thymosin beta-4. See the TB-500 page. Most talked about for general recovery, flexibility and cell migration to injury sites.
- Together they are sold as the "Wolverine" stack, often pre-mixed 1:1 in one vial. See the BPC-157 + TB-500 blend.
Where each one comes from
BPC-157 was first described in the early 1990s by researchers in Zagreb, who were looking at protective factors in gastric juice. The "BPC" stands for Body Protection Compound. The version sold today is a synthetic 15-amino-acid sequence.
TB-500 is derived from thymosin beta-4, a protein found in nearly every human cell and studied since the 1980s. The compound sold as TB-500 is a shorter synthetic fragment, and it also has a long grey-market history in horse racing, which is why you will see it discussed in veterinary and anti-doping contexts.
How they are thought to work
Nobody has a complete picture for either one, so treat every mechanism below as a working theory.
BPC-157
In animal studies it is associated with new blood vessel formation and with signalling that supports repair at the site of an injury. Much of the published work comes from a small number of research groups, which is one reason many scientists want independent replication.
TB-500
It is thought to affect actin, a structural protein that cells use to move. The idea is that it helps repair cells migrate to damaged tissue. Because it is thought to act more systemically, people often describe it as a "whole-body" recovery peptide, though that is more of a community label than a proven property.
Key differences at a glance
- Size and type: BPC-157 is a short, stable-ish fragment; TB-500 is a synthetic fragment of a larger natural protein.
- Half-life: BPC-157 is reported at roughly 30 minutes systemically; TB-500 is reported at a couple of hours. These are rough figures from limited data.
- Typical dosing pattern: BPC-157 is usually discussed as small, frequent doses (often daily). TB-500 is often discussed at larger, less frequent doses (for example a couple of times a week). Both are community-reported ranges, not trial-derived.
- Typical focus: BPC-157 for localised issues and gut; TB-500 for broader recovery. Again, this is community framing.
- Human evidence: Very limited for both. Anyone who says either is "proven" is overstating it.
Why are they stacked?
The reasoning is simple: if the two act on different parts of repair, they might complement each other. One is proposed to support blood vessel growth and repair signalling, the other cell movement. That is a hypothesis, not a result. Nobody has run a proper human trial of the pair, so we do not know whether the combination does more than either alone, the same, or nothing.
There is also a convenience factor. A pre-mixed vial means one injection instead of two. And there is a marketing factor: the stack has a catchy nickname, which sells vials.
The catch with pre-mixed 1:1 vials
If the dosing patterns for the two peptides differ (small daily BPC-157, larger less frequent TB-500), a fixed 1:1 vial forces compromise. To reach a TB-500 dose people describe as typical, you may end up taking far more BPC-157 than usual. Separate vials let you set each independently. We cover this trade-off in more detail in peptide blends explained.
The same logic applies to three-way blends such as GLOW, which adds the copper peptide GHK-Cu to the pair.
Side effects and risks
Both have been described as well tolerated in anecdotal reports, but that is not the same as safe. Reported issues include injection-site irritation, headaches, fatigue, nausea, flushing and lethargy. Because there is almost no long-term human data, unknown risks matter more than known ones.
Two theoretical concerns come up repeatedly. Both peptides are associated with promoting blood vessel growth and cell proliferation in animal work, so people with a history of cancer, or who are at risk, have good reason to be cautious. This is a theoretical concern rather than a demonstrated harm, but it is exactly the type of question human trials would need to answer.
TB-500 is also on the World Anti-Doping Agency's list of prohibited substances in sport, via its relationship to thymosin beta-4. If you are a tested athlete, check the current rules.
The biggest practical risk is often not the peptide itself but the product: wrong dose, contamination, or something else entirely in the vial. Read how to spot fake or under-dosed peptides and the safer use guide.
Which one gets talked about for what?
In community discussion, BPC-157 tends to come up for tendon and joint niggles, gut complaints and general soft-tissue injury. TB-500 tends to come up for broader recovery, flexibility and muscle injuries. Both are used "just in case" by people with no injury at all, which has no evidence behind it.
If you are trying to work out what fits your situation, the find your goal page is a more neutral place to start than a stack recommendation. And if you have an actual injury, a physio or GP will do something that is evidence-based; research peptides are not a replacement for that.
Bottom line
BPC-157 and TB-500 are different molecules with different proposed mechanisms, which is the whole logic of stacking them. But that logic is a hypothesis built on animal data and personal accounts. If you are weighing them up, the honest picture is: interesting biology, thin human evidence, unlicensed products of variable quality, and a fixed-ratio blend that limits how you can dose. Go in with eyes open.
Common questions
What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-amino-acid peptide linked to gastric juice and mostly discussed for localised tissue and gut healing, while TB-500 is a synthetic fragment related to thymosin beta-4 and discussed for broader recovery. They are proposed to work in different ways, though evidence for both is mostly from animals.
Why do people take BPC-157 and TB-500 together?
The theory is that they act on different parts of tissue repair and so may complement each other. That has not been tested in human trials, so it remains a hypothesis.
Is the BPC-157 and TB-500 stack proven to work?
No. There are no controlled human trials of the combination, and both individual peptides have very limited human data. Most claims come from animal studies and anecdotal reports.
Are BPC-157 and TB-500 legal?
Neither is a licensed medicine in the UK, and they are sold as research chemicals. TB-500 is also on the prohibited list in sport, so tested athletes should check the current rules.